CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

The company launched a Phase 2 Long COVID study to evaluate whether immune activation with Anktiva can improve recovery by ...

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

Scientists have discovered how two transcription factors form a reciprocal regulatory circuit that controls T-cell exhaustion ...

A team of researchers at the Georgia Institute of Technology and Emory University has developed a deep-ultraviolet (UV) microscopy method that can ...

SOUTH SAN FRANCISCO, Calif--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Researchers developed MIL33B, a high-affinity antibody that selectively targets the tumor-associated 4Ig-B7-H3 isoform while ...

Researchers at the Max Delbrück Center and the University of Oxford have found that a cellular housekeeping function called autophagy—by which cell components are broken down and recycled—plays a ...

A team of researchers at the Georgia Institute of Technology and Emory University has developed a deep-ultraviolet (UV) ...